Subject: (Copy) NIH GUIDE - Vol. 19, No. 14, April 6, 1990
From: Dot Baker <[email-masked]>
To: [email-masked]
Date: Thu, 05 Apr 90 08:41 EST

Paul,
   H E L P -  The first two transmissions I sent to you this morning
were dated wrong.  They should have been as follows:
 RFAHL-90-06-B.040690 and RFAAI90-03.040690.  Can you correct?  Please
let me know before I make the announcement to the listserver.
     Please post this to the NIH listserver as: NIHGUIDE.040690.
Thanks,
       Dottie
 ---------------------------- Text of forwarded message -----------------------
     
X-comment: NIH Guide (including TOC) contained 15 pages (1200 lines)
X-comment: RFAs described:  HL-90-06-B, DK-90-09, AI-90-03

     

     
NIH GUIDE - Vol. 19, No. 14, April 6, 1990

                                   NOTICES

WORLD AIDS FOUNDATION ..................................(84/133)............. 1
Index:  WORLD AIDS FOUNDATION

                   NOTICES OF AVAILABILITY (RFPs AND RFAs)

ANALGESIC AND BIOCHEMICAL RESPONSES TO PERIPHERAL OPIATES IN
DENTAL PAIN PATIENTS (RFP) .............................(139/172)............ 2
National Institute of Dental Research
Index:  DENTAL RESEARCH

POSTMORTEM STUDIES OF PAINFUL PERIPHERAL NEUROPATHY:  ABNORMALITIES OF
NEUROPEPTIDE SYNTHESIS AND RECEPTOR REGULATION (RFP) ...(175/209)............ 2
National Institute of Dental Research
Index:  DENTAL RESEARCH

OPERATION OF A FACILITY FOR THE STUDY OF INFECTIOUS AGENTS VACCINES AND
ANTIMICROBIALS IN ADULT AND PEDIATRIC HUMAN SUBJECTS (RFP) ..(212/263)....... 2
National Institute of Allergy and Infectious Diseases
Index:  ALLERGY, INFECTIOUS DISEASES

CENTRALIZED PATHOLOGY UNIT FOR SICKLE CELL DISEASE (RFP) ....(266/295)....... 3
National Heart, Lung, and Blood Institute
Index:  HEART, LUNG, BLOOD

STUDY OF CAUSES AND COURSE OF DISABILITY IN OLDER WOMEN (RFP) ..(298/351).... 3
National Institute on Aging
Index:  AGING

CLINICAL UNITS FOR ASYMPTOMATIC CARDIAC ISCHEMIA PILOT STUDY (RFP) .......... 4
National Heart, Lung, and Blood Institute               (354/412)
Index:  HEART, LUNG, BLOOD

STEM CELLS FOR ENGRAFTMENT:  BLOOD CELLS FOR TRANSFUSION (RFA HL-90-06-B) ... 5
National Heart, Lung, and Blood Institute          (415/465, 1204/1606)
Index:  HEART, LUNG, BLOOD

RESEARCH ON THE MOLECULAR BASIS OF CYSTIC FIBROSIS (RFA DK-90-09) ........... 5
National Institute of Diabetes and Digestive and Kidney Diseases
Index:  DIABETES, DIGESTIVE DISEASES, KIDNEY DISEASES  (468/619, 1609/1893)

SEXUALLY TRANSMITTED DISEASES COOPERATIVE RESEARCH CENTERS (RFA AI-90-03) ... 7
National Institute of Allergy and Infectious Diseases  (622/781, 1896/2681)
Index:  ALLERGY, INFECTIOUS DISEASES

                        ONGOING PROGRAM ANNOUNCEMENTS

RESEARCH CAREER AWARDS IN THROMBOSIS (PA-90-01) ........(787/1051)........... 9
National Heart, Lung, and Blood Institute
Index:  HEART, LUNG, BLOOD

INVESTIGATIONS INTO THE BIOLOGY OF THE RENAL MICROVASCULATURE (PA-90-02) ....12
National Institute of Diabetes and Digestive and Kidney Diseases  (1054/1191)
Index:  DIABETES, DIGESTIVE DISEASES, KIDNEY DISEASES

                                   NOTICES

WORLD AIDS FOUNDATION
     
P.T. 34; K.W. 0715008, 0745027, 0720005
     
The World AIDS Foundation (WAF) announces its intent to support research and
education relating to AIDS in the developing world.  The goal of the WAF is to
facilitate information exchange and to assist developing countries to respond
to the AIDS pandemic.
     
The Foundation is particularly interested in projects which are catalytic, and
once in place could have a multiplicative effect.  The WAF is specifically
interested in supporting:
     
A) short-term, in-country training for clinicians, allied health professionals
and technicians;
     
B) fellowships to support training for national experts;
     
C) development and testing of new concepts and demonstrations for preventing
the spread of HIV; and
     
D) highly focused workshops which enhance the scientific process and transfer
knowledge needed in the effort against HIV infections and AIDS.
     
The limit of any single funding request to WAF is $200,000.
     
Application Procedures
     
Concept letters and applications may be prepared in English or French.
Applicants should submit concept letters for initial consideration.  Following
review of concept proposals, applicants may be invited to submit complete
proposals.
     
For further information please contact:
     
World AIDS Foundation
c/o Assistant Secretary for Health
Department of Health and Human Services
200 Independence Avenue, S.W.
Washington, D.C.  20201
U.S.A.
     
or
     
World AIDS Foundation
c/o Director
Institut Pasteur
28 Rue du Docteur Roux
75724 Paris, Cedex 15
FRANCE

                   NOTICES OF AVAILABILITY (RFPs AND RFAs)

ANALGESIC AND BIOCHEMICAL RESPONSES TO PERIPHERAL OPIATES IN DENTAL PAIN
PATIENTS
     
RFP AVAILABLE:  NIH-NIDR-2-90-5R
     
P.T. 34; K.W. 0755015, 0715148, 0715150, 0740025
     
National Institute of Dental Research
     
This acquisition is for a proposed double-blind, randomized,
placebo-controlled, single center clinical trial using dental pain patients to
evaluate the following hypotheses:  (1) Does local administration of opioids
produce a peripherally-mediated analgesia?  (2) Is this analgesia due to
selective activation of opiate receptors?  (3) Is this analgesia associated
with decreased levels of inflammatory mediators?  These hypotheses will be
evaluated in patients experiencing dental pain (due to acute periradicular
periodontitis) requiring periodontal ligament injections with collection of
pain reports and tissue perfusates for measurement of chemicals related to
pain and inflammation.  It is anticipated that one award will be made,
covering a two-year period of performance.
     
             NIH GUIDE - Vol. 19, No. 14, April 6, 1990 - Page 1
RFP No. NIH-NIDR-2-90-5R will be available on or about April 20, 1990, with
proposals due on or about June 1, 1990.
     
The RFP will be available upon written request to:
     
Marion L. Blevins
Contract Management Section
National Institute of Dental Research
National Institutes of Health
Westwood Building, Room 521
5333 Westbard Avenue
Bethesda, MD  20892

POSTMORTEM STUDIES OF PAINFUL PERIPHERAL NEUROPATHY:  ABNORMALITIES OF
NEUROPEPTIDE SYNTHESIS AND RECEPTOR REGULATION
     
RFP AVAILABLE:  NIH-NIDR-2-90-8R
     
P.T. 34; K.W. 0715140, 0715150, 0765010, 0760075, 0780020
     
National Institute of Dental Research
     
This proposed acquisition is for a two-year study to determine whether painful
peripheral neuropathies in humans are associated with abnormalities of spinal
cord neuropeptide synthesis and neuropeptide receptor regulation.  Such
abnormalities have been detected in rats with an experimental version of
painful peripheral neuropathy; the question addressed in this project is
whether or not similar abnormalities occur in humans.
     
The contractor will be required to attend autopsies of tissue donors with a
pre-morbid history of reflex sympathetic dystrophy or causalgia, obtain
properly identified segments of the spinal cord (in some cases brainstem), and
properly prepare the tissue samples for subsequent histology.  The project
officer will be responsible for recruiting tissue donors.  The contractor must
be available to travel to the autopsy sites within 1-3 hours notice from the
project officer.  It is anticipated that one award will be made.  RFP No.
NIH-NIDR-2-90-8R will be available on or about April 20, 1990, with proposals
due on or about June 4, 1990.
     
The RFP will be available upon written request to:
     
Marion L. Blevins
Contract Management Section
National Institute of Dental Research
National Institutes of Health
Westwood Building, Room 521
5333 Westbard Avenue
Bethesda, MD  20892

OPERATION OF A FACILITY FOR THE STUDY OF INFECTIOUS AGENTS VACCINES AND
ANTIMICROBIALS IN ADULT AND PEDIATRIC HUMAN SUBJECTS
     
RFP AVAILABLE:  NIH-NIAID-DIR-91-01
     
P.T. 34; K.W. 0715125, 1002045, 0740075, 0785035, 0403017
     
National Institute of Allergy and Infectious Diseases
     
The Laboratory of Infectous Diseases (LID), National Institute of Allergy and
Infectious Diseases (NIAID), studies infections in humans and evaluates the
effectiveness of various vaccines and antimicrobials in the prevention and
treatment of these diseases.  The purpose of the proposed contract is to
provide a facility and volunteers to study the biology of important viruses in
humans, to examine the immune response of the host to these viruses, and to
test new candidate vaccines for safety, genetic stability, immunogenicity,
transmissibility and protective efficacy.  Studies will include administration
of wild type viruses to volunteers in order to assess their virulence.
Subsequently, these viruses will be used to challenge vaccinated volunteers in
order to assess the extent of of immunity induced by candidate vaccines.
Studies with vaccines will include an evaluation of their safety,
immunogenicity, transmissibility, and protective efficacy.  The major
infectious agents of interest to the LID include influenza A and B viruses,
paramyxoviruses, rotaviruses, and other gastrointestinal viruses such as the
Norwalk group of agents.  This contract will meet the Institute needs for a
nearby facility in which clinical and epidemiological studies on infectious
agents, vaccines, other biological products, and pharmaceuticals shall be
     
             NIH GUIDE - Vol. 19, No. 14, April 6, 1990 - Page 2
evaluated in healthy (adult and pediatric) volunteers in collaboration with
NIAID staff members.  Since there will be active collaboration on a day-to-day
basis between the investigators at the testing facility and NIAID scientist,
the proposed contract will require that the facility be located within one (1)
hour of the National Institutes of Health, Bethesda, Maryland, campus.
     
The Institute expects to make one award from this solicitation.
     
The Request for Proposals (RFP) will be available on or about April 3, 1990.
Any responsible offeror may submit a proposal which shall be due by the close
of business on June 4, 1990.
     
Requests for this RFP should be directed to:
     
Ms. Rosemary McCabe Hamill
Contracting Officer
Contract Management Branch
National Institute of Allergy and Infectious Diseases
Westwood Building, Room 707
5333 Westbard Avenue
Bethesda, MD  20892
     
Please provide this office with two self addressed labels.

CENTRALIZED PATHOLOGY UNIT FOR SICKLE CELL DISEASE
     
RFP AVAILABLE:  RFP-NHLBI-HB-90-03
     
P.T. 34; K.W. 0715032, 0785165, 0755018
     
National Institute of Heart, Lung, and Blood
     
The National Heart, Lung, and Blood Institute (NHLBI) is seeking a contractor
to establish a centralized laboratory to characterize and catalogue autopsy
and surgical specimens and correlate pathological findings with clinical data
to determine more precisely the causes of death in patients with sickle cell
disease.  This unit shall be a major determinant to our ability to accurately
assess causes related to mortality in sickle cell disease.
     
RFP-NHLBI-HB-90-03 was issued on March 20, 1990, with proposals due on May 9,
1990.  One (1) award is anticipated by the Government and the contract period
is sixty 60 months.
     
To expedite requests for this solicitation, please furnish three (3)
self-addressed labels with your mailing address and cite RFP-NHLBI-HB-90-03.
     
Requests for copies of the RFP should be sent to:
     
Jack E. Jackson
Contracting Officer
DBDR Contracts Section, Contracts Operations Branch
National Heart, Lung, and Blood Institute
Federal Building, Room 5C14
Bethesda, MD  20892

STUDY OF CAUSES AND COURSE OF DISABILITY IN OLDER WOMEN
     
RFP AVAILABLE:  RFP-NIH-AG-90-08
     
P.T. 34, II; K.W. 0710010, 0715000, 0755030
     
National Institute on Aging
     
The Epidemiology, Demography and Biometry (EDB) Program of the National
Institute on Aging (NIA) proposes to support, through a research and
development contract, an epidemiologic study on the causes and course of
physical disability in older women.  The overall goal of this study is to
screen a population of non-institutionalized women age 65 and older, to select
those with moderate to severe physical disability, to comprehensively evaluate
these women to gain an understanding of the diseases and conditions
responsible for their disabilities, and then to follow them prospectively over
a period of 3 years with twice yearly assessments.  Goals for data collection
shall be derived from a priori hypotheses.
     
For the purpose of this solicitation, disability is defined as a deviation or
alteration in normal functional performance.  Physical disability specifically
     
             NIH GUIDE - Vol. 19, No. 14, April 6, 1990 - Page 3
relates to dependence in some aspect of physical functioning.  The focus of
this study is on physical functioning, but other domains of functioning, such
as cognitive, psychological, and social functioning, will also be assessed.
These other domains of functioning will be approached as important modifiers
of physical functioning and disability.  In analyses, these domains of
functioning will be considered as independent variables which have a potential
impact on physical functioning in much the same way that underlying chronic
diseases, demographics, health behaviors, and other independent variables may
have such an impact.  The overall approach incorporates a general goal of
understanding factors involved in the loss of autonomy and the development of
dependence on others to perform a variety of tasks which older persons want to
do and usually can do given good health and vitality.
     
The Institute expects to make one award from this solicitation.
     
The issuance of the Request for Proposals (RFP) will be on or about April 12,
1990, and proposals will be due by the close of business on June 14, 1990.
     
Any responsible offeror may submit a proposal and will be considered by the
Government.
     
Request for the RFP should be directed to:
     
Ms. Bonnie Keane
Contracting Officer
Research Contracts Branch
National Institutes of Health
Building 31, Room 1B44
Bethesda, MD  20892
     
Please provide this office with two self-addressed mailing labels.

CLINICAL UNITS FOR ASYMPTOMATIC CARDIAC ISCHEMIA PILOT STUDY
     
RFP AVAILABLE:  RFP NIH-NHLBI-HV-90-08
     
P.T. 34; K.W. 0715040, 0745070, 0785210, 0755015
     
National Heart, Lung, and Blood Institute
     
The National Heart, Lung, and Blood Institute will do a study to determine the
efficacy and safety of the three different treatment strategies in reducing
cardiac ischemia in patients with coronary artery disease (CAD).  Patients
will be randomly assigned to usual symptom-guided medical care; stepped
maximal, ambulatory ECG-directed, medical therapy; or mechanical
revascularization (angioplasty and/or surgery).  The principal endpoint for
these comparisons is a reduction of ambulatory ECG-documented ischemia.  To
accomplish this objective this program proposes to recruit 10-12 Clinical
Units with access to sufficient numbers of patients with documented CAD and
positive exercise stress test.  Outcomes of assigned treatment such as
non-fatal MI, type and frequency of revascularization, hospitalization for
unstable angina, change in both myocardial perfusion and left ventricular
function assessed by radionuclide scintigraphy, and mortality will be
monitored for all patients in all treatment groups.  It will be necessary to
enroll 600 patients or approximately 60 patients per Clinical Unit.  The
expectation of this study is determination of the safety and efficacy of
treatment of cardiac ischemia in patients with documented CAD.  Methodology to
be considered includes contrast coronary angiography and radionuclide
scintigraphy (both myocardial perfusion and left ventricular function).
Definition of specific data to be collected, methods of collection, and
management of the data are necessary, as well as proposed criteria to evaluate
and interpret the results in close collaboration with the Clinical
Coordinating Center.  This incrementally funded contract will be awarded for
36 months.
     
This is not a Request for Proposals.  RFP NHLBI-HV-90-08 was released on March
10, 1990, with proposals due on or about April 30, 1990.  Ten (10) to twelve
(12) awards are anticipated by the Government.  Your written request should
include three (3) labels, self-addressed with your mailing address, and must
cite RFP No. NHLBI-HV-90-08.
     
Request for copies of the RFP should be sent to the following address:

     

     
             NIH GUIDE - Vol. 19, No. 14, April 6, 1990 - Page 4
Sharon M. Kraft, Contract Specialist
HLVD Contracts Section, Contracts Operations Branch, DEA
National Heart, Lung, and Blood Institute
Federal Building, Room 4C04
National Institutes of Health
Bethesda, MD  20892
Telephone:  (301) 496-6838
     
Note:  This announcement is published for information purposes.  It appeared
in the Commerce Business Daily on March 8, but did not make the NIH Guide for
prompt publication.  NHLBI was unable to extend the date that responses are
due.

STEM CELLS FOR ENGRAFTMENT:  BLOOD CELLS FOR TRANSFUSION
     
RFA AVAILABLE:  HL-90-06-B
     
P.T. 34; K.W. 0750010, 0780015, 0710070, 1002008, 0760020
     
National Heart, Lung, and Blood Institute
     
Application Receipt Date:  August 1, 1990
     
The Blood Diseases and Blood Resources Branches of the Division of Blood
Diseases and Resources (DBDR), National Heart, Lung, and Blood Institute
(NHLBI), announce the availability of a Request for Applications (RFA) on the
above subject.  Copies of the RFA are currently available from staff of the
NHLBI.  Awards will be made to foreign institutions only for research of very
unusual merit, need, and promise.
     
This special program will support research on the development and utilization
of in vitro culture systems for stem cells.  This research will help to gain
basic insights into the control of hematopoiesis and stem cell engraftment and
to produce stem cells and other specific cell populations that might be useful
in transplantation and transfusion therapies.
     
The support mechanism for this FIVE-year program will be the traditional
individual research grant (R01).  Although approximately $1,500,000 (for
direct plus indirect costs) for this program is included in the financial
plans for fiscal year 1991, award of grants pursuant to this RFA is contingent
upon receipt of funds for this purpose.  The specific number of awards to be
funded depends on the merit and scope of the applications received and the
availability of funds.
     
Requests for copies of the RFA may be addressed to:
     
Alan S. Levine, Ph.D.
Chief, Blood Diseases Branch, DBDR
National Heart, Lung, and Blood Institute
Federal Building, Room 5A12
Bethesda, MD  20892
Telephone:  (301) 496-5911
FAX:  (301) 496-9940
     
or
     
Milton J. Hernandez, Ph.D.
Health Scientist Administrator
Blood Resources Branch, DBDR
National Heart, Lung, and Blood Institute
Federal Building, Room 504
Bethesda, MD  20892
Telephone:  (301) 496-1537
FAX:  (301) 496-9940

RESEARCH ON THE MOLECULAR BASIS OF CYSTIC FIBROSIS
     
RFA AVAILABLE:  DK-90-09
     
P.T. 34; K.W. 0765035, 0755030, 0790005, 1013004, 0755020
     
National Institute of Diabetes and Digestive and Kidney Diseases
     
Letter of Intent Receipt Date:  June 15, 1990
Application Receipt Date:  August 1, 1990

             NIH GUIDE - Vol. 19, No. 14, April 6, 1990 - Page 5
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
and the Cystic Fibrosis Foundation (CFF) invite investigator-initiated
research grant applications to define and characterize the molecular
pathophysiology of cystic fibrosis (CF) and the membrane transport processes
associated with the etiology and pathogenesis of CF.
     
Applications submitted to the NIH will be reviewed according to normal NIH
peer review procedures.  Applications judged meritorious but not funded by the
NIH may be submitted by the applicant, along with the NIH-prepared summary
statement, to the CFF for possible funding by the Foundation.
     
OBJECTIVES
     
It is the intention of the NIDDK and the CFF to stimulate research on the CF
defect(s) by support of meritorious applications proposing:
     
  o  To study processes involved in the expression and/or
     over-expression of the normal or mutant products of the CF gene.
     
  o  To study the role of the CFTR protein, or other relevant membrane
     proteins, in biochemical and physiological events related to
     defective ion transport in CF.
     
  o  To elucidate the mechanisms by which aberrant control of ion
     transport pathways in epithelial cells leads to the pathophysiology
     of CF.
     
  o  To develop appropriate model systems for studying the regulation of
     defective cellular processes in CF.
     
  o  To study epithelial cell membrane associated proteins other than
     CFTR, such as components of transport systems or signal
     transduction systems, with relevance to understanding the mechanism
     of the defective ion transport in CF.
     
  o  To apply novel biophysical approaches to structural studies of
     membrane transport systems, or their components, or their crystals
     as they pertain to understanding the defective ion transport in CF.
     
  o  To identify and characterize potential therapeutic agents capable
     of modulating the transport defect in CF.
     
  o  To develop and characterize techniques of gene transfer into cells
     specifically useful in studying and/or ultimately in correcting the
     transport defect in CF.
     
MECHANISM OF SUPPORT
     
The National Institutes of Health (NIH) will provide support for this program
through the regular research project grant (R01).  Those grants funded by the
CFF will follow CFF guidelines.  The CFF support will be limited to three
years duration with a maximum of eight percent indirect costs.
     
Applications submitted to the NIH in response to this Request for Applications
(RFA) that are judged scientificaly meritorious but not funded by the NIDDK
may be submitted by the applicant to the CFF for consideration for funding.
     
The NIDDK and the CFF each plan to support approximately five to seven
applications submitted in response to this solicitation; however, the specific
number to be funded will depend upon the overall merit, the scope of the
applications received, and availability of funds.
     
REVIEW PROCEDURES AND CRITERIA
     
Upon receipt, applications will be reviewed (initially) by the Division of
Research Grants (DRG) for completeness.  Applications also will be reviewed by
NIDDK staff for their responsiveness to the objectives of this RFA.  If an
application submitted in response to this RFA is identical to a research grant
application already submitted to the NIH for review, the applicant will be
asked to withdraw the pending application before the new one is accepted.
     
The National Heart, Lung, and Blood Institute also has an interest in
supporting areas of research covered by this RFA.  Should a question of
program overlap arise for a given application, the DRG Referral Guidelines
will prevail in the institute assigment of the applications.
     
Applications in response to this RFA will be reviewed on a nationwide basis
and in accord with the usual NIH peer review procedures.  Review criteria
     
             NIH GUIDE - Vol. 19, No. 14, April 6, 1990 - Page 6
include the extent of relevance and/or contribution of the proposed research
to the overall goals and objectives of the RFA.
     
METHODS OF APPLYING
     
Letter of Intent
     
Prospective applicants are encouraged to submit an optional one-page letter of
intent, which includes the title of the proposed project and identification of
all participating institutions.  This letter should be received no later than
June 15, 1990, and should be sent to the program representative listed under
Inquiries.
     
Format for Applications:
     
Applications should be submitted on Form PHS 398 (rev.  10/88), which is
available from an applicant institution's Office of Sponsored Research or from
the NIH Division of Research Grants.  To identify the application as a
response to this RFA, check "yes" on item two of page one of the application
and enter the title "The Molecular Basis of Cystic Fibrosis" and the RFA
Number DK-90-09.
     
Application Procedure:
     
The original and four copies of the application should be sent or delivered
to:
     
Application Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**
     
Two additional copies of the application must be sent under separate cover to:
     
Review Branch
National Institute of Diabetes and Digestive and Kidney Diseases, NIH
Westwood Building, Room 406
Bethesda, MD 20892
     
Inquiries:
     
For further information, investigators are encouraged to contact:
     
Nancy Lamontagne, Ph.D.
Director, Cystic Fibrosis Program
Division of Diabetes, Endocrinology, and Metabolic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 607
Bethesda, MD 20892
Telephone:  (301) 496-4980
     
This program is described in the Catalog of Federal Domestic Assistance No.
13.847, Diabetes, Endocrinology, and Metabolic Diseases.  Awards will be made
under the authority of the Public Health Service Act, Title III, Section 301
(Public Law 78-410, as amended; 42 USC 241) and administered under PHS grant
policies and Federal Regulations most specifically at 42 CFR Part 52 and CFR
Part 74.  This program is not subject to the intergovernmental review
requirements of Executive Order 12372 or Health Systems Agency review.

SEXUALLY TRANSMITTED DISEASES COOPERATIVE RESEARCH CENTERS
     
RFA AVAILABLE:  AI-90-03
     
P.T. 04; K.W. 0715182, 0710030, 0715125, 0404000, 0785035, 0403004
     
National Institute of Allergy and Infectious Diseases
     
Letter of Intent Receipt Date:  August 1, 1990
Application Receipt Date:  October 10, 1990
     
The Sexually Transmitted Diseases (STD) Branch of the Division of Microbiology
and Infectious Diseases (DMID) of the National Institute of Allergy and
Infectious Diseases (NIAID) invites grant applications for the establishment
of a network of Sexually Transmitted Diseases Cooperative Research Centers
(STD CRCs).  The CRCs will provide a multi-disciplinary, systematic, sustained
approach to sexually transmitted diseases research.  The intent of this
     
             NIH GUIDE - Vol. 19, No. 14, April 6, 1990 - Page 7
approach is to bridge the basic research, and clinical and epidemiologic
research arenas; to facilitate intervention-oriented behavioral research for
prevention and control of STDs; to foster interaction with both local medical
and lay communities; to develop potential sites for future multi-center
clinical trials; and to provide opportunities for interaction, dialogue and
planning among STD investigators through STD Branch coordination of regularly
scheduled workshops.
     
RESEARCH OBJECTIVES AND SCOPE
     
The purpose of this RFA is to stimulate exceptionally high quality,
multi-disciplinary, collaborative STD research efforts.  This will be
accomplished by collaborations among the disciplines from the basic research,
clinical and epidemiological, and behavioral arenas.  Interdisciplinary
collaborations should both link disciplines within a single arena (e.g.,
molecular biology and immunology) and reach across to link disciplines in
different arenas (e.g., microbiology and social/clinical psychology).  In
addition to the importance of utilizing a multi-disciplinary approach,
specific programmatic requirements are as follows:
     
DEFINITION OF RESEARCH SCOPE:  Research must focus on a minimum of three STD
pathogens or syndromes, each of which should be approached through
multi-disciplinary collaborations.  STD CRC applications must include at least
two projects that link disciplines within a single arena and at least one
project that links disciplines in two different arenas.  Applications must
therefore include a minimum of three research projects.  Applicants are
strongly encouraged, however, to propose three or more projects linking
disciplines within a single arena and two or more projects linking disciplines
across two different arenas for a total of at least five projects.
     
CLINICAL FACILITY:  In order to bridge the basic research and clinical arenas,
STD CRCs must offer a strong clinical facility with accessible patient
populations that are appropriate to answering STD research questions.
Adolescents, inner city minority groups, and antenatal, family planning and
STD clinic patients are examples of potentially relevant populations.  To
further integrate clinical and basic biomedical research initiatives, it is
also permissible for projects to include post-residency personnel who spend a
maximum of one third of their time in clinical activities related to the
research focus of the project.
     
Applications must also include at least one of the following components.  It
should be emphasized, however, that no single application is expected to
include all of these components.  Other creative approaches may be proposed in
addition to, but not instead of, these components.
     
INCLUSION OF A STRONG, INNOVATIVE, BEHAVIORAL COMPONENT TO STD CRC RESEARCH
PROJECTS:  STD CRCs, because of their multi-disciplinary approach, are in a
unique position to design and evaluate behavioral interventions by examining
microbiologic as well as behavioral outcomes.
     
OUTREACH ACTIVITIES TO THE LAY AND THE LOCAL MEDICAL COMMUNITIES:  Outreach
activities 1) may be nonhealth-care facility based, 2) should usually focus on
non-patient populations, and 3) must include an evaluation component.
     
LONG-TERM, ONGOING COLLABORATIONS WITH FOREIGN INSTITUTIONS IN DEVELOPING
COUNTRIES:  Proposals for development of long-term, ongoing collaborations
between STD CRCs and foreign institutions in developing countries will be
considered.  The collaboration not only must be beneficial to the foreign
country, but also must offer the potential for collection of STD data which
are pertinent to U.S. populations and which could not be generated as
effectively in the United States.
     
An optional component which may also be helpful in achieving STD CRC research
goals is a developmental funds pool:
     
DEVELOPMENTAL FUNDS FOR NEW INVESTIGATOR OR PILOT PROJECTS:  Within budget
proposals, applicants may request developmental funds for new investigator
projects or pilot projects.  It is hoped that this type of support may be used
for objectives such as the rapid, "pilot" exploration of new ideas and
approaches, the generation of preliminary data for traditional NIH grant
applications, or the development of new "programs."
     
In designing specific projects, applicants are encouraged to consider research
proposals which focus on important, yet underserved, areas of STD
investigation.  Areas and organisms of particular interest include:  Sequelae
of STDs in women, genital ulcer disease, and human papillomavirus (hpv)
infection.

             NIH GUIDE - Vol. 19, No. 14, April 6, 1990 - Page 8
STD VACCINE DEVELOPMENT also continues to be an important priority.  Ongoing
basic research directed towards vaccine development, particularly for
pathogens such as N. gonorrhoeae, T. pallidum, and herpes simplex virus type 2
(HSV-2) are research areas of interest.  In order to make critical advances in
this area, functional collaborations between immunologists and microbiologists
focused on pathogenesis will be extremely important.
     
WORKSHOP PARTICIPATION:  Successful applicants will be expected to participate
in regularly scheduled workshops that will be held at least twice yearly to
share STD research advances; to discuss STD research needs and opportunities;
and to develop new collaborative protocols which may include multi-center
studies.
     
MULTI-CENTER TRIALS:  Because the STD CRCs will form the nucleus of a network
of high-quality STD research environments, STD CRC applicants are strongly
encouraged to be receptive to future participation in the development of
multi-center trials.
     
Applicants are urged to give added attention where feasible and appropriate to
the inclusion of females and of minorities in study populations for STD CRCs.
If either females or minorities are not included in a given study, a clear
rationale for their exclusion should be provided.
     
MECHANISM OF SUPPORT
     
Awards will be made as COOPERATIVE AGREEMENTS.  These are interactive
assistance relationships in which an ongoing collaborative relationship exists
between the NIAID staff and the investigative team.  The NIAID anticipates
making two to four awards as a result of this RFA.  The final number of awards
to be made is dependent upon the availability of funds.  It is estimated that
the initial year's direct and indirect costs will not exceed $1.2 million for
each award.  Awards will be made for a project period of up to five years.
The earliest possible award date is July 1, 1991.
     
METHOD OF APPLYING
     
A copy of the complete RFA should be obtained before beginning the application
process.  For further information, or to receive a copy of the complete RFA,
please contact:
     
Dr. Judith N. Wasserheit
Chief, Sexually Transmitted Diseases Branch
Division of Microbiology and Infectious Diseases
Westwood Building, Room 749
NIAID, National Institutes of Health
Bethesda, MD  20892
Telephone:  (301) 402-0443
     
Prospective applicants are asked to submit, by August 1, 1990, a short letter
of intent that includes a descriptive title and the names and affiliation(s)
of proposed key investigators for each of the proposed research projects.
Letters of intent should be sent to Dr. Olivia Preble at the following
address:
     
Dr. Olivia Preble
Acting Chief, Microbiology and Immunology Review Section
Program and Project Review Branch
Westwood Building, Room 3A-10
NIAID, National Institutes of Health
Bethesda, MD  20892
Telephone:  (301) 496-8208

                        ONGOING PROGRAM ANNOUNCEMENTS

RESEARCH CAREER AWARDS IN THROMBOSIS
     
PA:  PA-90-01
     
P.T. 34; K.W. 0715040, 0785035, 0745020, 0745070, 0404000
     
National Heart, Lung, and Blood Institute
     
The objective of the Research Career Awards in Thrombosis is to support the
professional development of individuals who can serve expanding and evolving
research, teaching, and clinical requirements in the area of thrombosis and
thromboembolic disorders.  This announcement emphasizes the need for increased
     
             NIH GUIDE - Vol. 19, No. 14, April 6, 1990 - Page 9
research training in this area and encourages individuals to submit
applications for support using the three existing research career development
awards sponsored by the NHLBI:  Physician Scientist Award (PSA) (K11);
Clinical Investigator Award (CIA) (K08); and Research Career Development Award
(RCDA) (K04).
     
Applications submitted in response to this announcement will be brought to the
attention of the National Heart, Lung, and Blood Advisory Council and or
another appropriate Council and will receive consideration for support by the
appropriate Institute.
     
BACKGROUND
     
Thromboembolic events give rise to serious clinical disease and contribute
significantly to the nation's health care burden.  Both thrombosis and
atherosclerosis are important factors in cardiovascular disease.  In 1987,
they accounted for almost one million deaths.  In addition, 150,000 persons in
the United States died of cerebrovascular disease, the third leading cause of
death in 1987.  The economic burden of cardiovascular diseases in 1984 was an
estimated $110 billion.  It is further estimated that six million episodes of
venous thrombosis occur annually accounting directly for 10,000 hospital
deaths due to pulmonary embolism.  In all, the impact of thromboembolism and
thromboembolic disorders on mortality and morbidity is impressive.
     
Substantial progress has been made towards understanding the basic mechanisms
operating in thrombosis, the impact of thromboembolic phenomena on organ
systems, and the techniques needed to prevent and treat thrombosis.  Specific
areas of progress include molecular and cellular pathology of thrombosis,
biochemistry of coagulation and fibrinolysis, biology of vessel growth,
endothelial cell function and vascular reactivity, the blood-vessel interface,
and the interaction of cellular components with the vascular endothelium, thus
contributing to the development of thrombosis.  Therapeutic options are now
available for the management of thrombosis and other treatment modalities are
under development.  Prevention of thrombosis and thromboembolic disorders,
development of more effective therapies, and the appropriate choice of
treatment demands a thorough understanding of all these facets of the subject.
     
The major strides which have taken place in basic and clinical understanding
of thrombosis suggest that an unprecedented opportunity exists for major
improvements in the way patients with these disorders are managed.  In
addition, the enormous health and economic impact of arterial and venous
thrombosis argues strongly for giving this area increased attention.  This
announcement is prompted by the need to provide increasing numbers of basic
and clinical investigators in the area of thrombosis and thromboembolic
disorders, so that rapid and effective progress in the area can be made.
     
Candidates submitting research career development proposals in response to
this program announcement should focus on topics such as those listed below:
     
  o  basic research projects that lead to better understanding of
     mechanisms in thrombosis and thromboembolic disorders;
  o  clinical research projects that will improve the detection of
     high-risk patients and prevent thrombosis;
  o  applied research projects that lead to improved diagnosis and
     therapeutic approaches to thrombosis;
  o  effective, safe monitoring techniques for patients undergoing
     anti-thrombotic therapy; or
  o  studies that deal with the logistical, economic, social, and
     behavioral aspects of thrombosis and thromboembolic disease.
     
Individual training programs that offer research and career development
opportunities in all areas related to thrombosis and thromboembolic disorders
are welcomed.  If candidates do not possess skills in research design and
biostatistics, the applicant should consider including these training areas in
the plan.  The background training of candidates for these research training
programs may have been in hematology, cardiology, surgery, orthopedics,
radiology, clinical pharmacology, pathology, or epidemiology.
     
MECHANISMS OF SUPPORT
     
The three support mechanisms for these Research Career Awards in Thrombosis
are summarized in this announcement and provide for several levels of career
development.  Detailed guidelines for each of the three support mechanisms can
be obtained from your business office, from the Division of Research Grants,
NIH, (301) 496-7441, or from Dr. Fann Harding, Division of Blood Diseases and
Resources, (301) 496-1817.  Only citizens and non-citizen nationals are
eligible for support under these programs.

             NIH GUIDE - Vol. 19, No. 14, April 6, 1990 - Page 10
A. PHYSICIAN-SCIENTIST AWARD - PSA (K11)
     
Provides 3-5 years of support based on previous experience of the applicant.
A full two-phase award may be requested by physicians inexperienced in
research to undertake 5 years of special study in basic science with a
supervised research experience.  Newly trained clinicians are encouraged,
during Phase I of the award, to develop independent research skills and
experience in a fundamental science which can be applied, during Phase II,
towards problems in thrombosis and thromboembolic disorders.  Investigators
having some research experience may elect to apply for Phase II only of the
PSA.
     
  o  Award is made to an institution on behalf of a candidate whose
     primary sponsor is an accomplished basic science investigator who
     will provide guidance for the entire award period.
     
  o  Selection is by national competition.
     
  o  Training support is for up to 5 years for full-time effort.  Phase
     I entails 2 or 3 years of creative and detailed basic science
     learning experience; Phase II entails 2 or 3 years of intensive
     research activity under general guidance of a qualified sponsor.
     
  o  Salary is up to $40,000 per year plus fringe benefits for 100
     percent effort.
     
  o  During Phase I, up to 10 percent of the primary sponsor's salary
     and commensurate fringe benefits may be requested.
     
  o  Research support may be requested in an amount not to exceed
     $10,000 per year and increasing to $20,000 per year in Phase II.
     
  o  Salary supplementation from non-federal sources is allowable.
     
  o  Indirect costs of 8 percent of total direct costs, exclusive of
     tuition, fees, and equipment expenditures, or actual rate,
     whichever is less, may be requested.
     
  o  Awardees must inform the NIH for each of five years following the
     completion of the award about academic status, publications, and
     research grants and contracts received.
     
  o  PSA application may not be submitted concurrently with other
     development awards, such as CIA, RCDA, FIRST Award, or Academic
     Award; however, the awardee is encouraged to apply for research
     support during the period of the award.
     
  o  Use application form PHS 398 (Rev.  10/88) with special PSA
     instructions.
     
B.  CLINICAL INVESTIGATOR AWARD - CIA (K08)
     
Provides support for a period of career development of 3-5 years for
individuals with the M.D. degree or other professional doctorates.  The
objective is to encourage the development of basic, clinical, and behavioral
research skills.  Candidates with previous research experience may apply for
an abbreviated program of development.  Applicants will usually have not less
than 3 years of postdoctoral clinical training nor more than seven years of
total postdoctoral clinical and research experience by the time an award is
made.
     
  o  Award is made to an institution on behalf of a candidate who has an
     appropriate sponsor willing to assume responsibility and provide
     guidance for candidate's research program.
     
  o  Selection is by national competition.
     
  o  Salary is up to $40,000 per year plus fringe benefits.
     
  o  Research support is provided in an amount not to exceed $10,000 per
     year.
     
  o  Training period is for 3-5 years for full-time effort.
     
  o  Salary supplementation from non-federal funds is allowable.
     
  o  Indirect costs of 8 percent of total direct costs or actual rate,
     whichever is less, may be requested.
     
             NIH GUIDE - Vol. 19, No. 14, April 6, 1990 - Page 11
  o  Awardees must inform the NIH for each of five years following the
     completion of the award about academic status, publications, and
     research grants and contracts received.
     
  o  CIA applications may not be submitted concurrently with other
     development awards, such as PSA, RCDA, FIRST Award, or Academic
     Award.  CIA awardees are, however, encouraged to apply for research
     support during the period of the award.
     
  o  Use application form PHS 398 (Rev.  10/88) with special CIA
     instructions.
     
C.  RESEARCH CAREER DEVELOPMENT AWARD - RCDA (K04)
     
Supports investigators who have demonstrated outstanding research potential.
Provides salary support only for investigators who normally have 5 years of
postdoctoral experience at the time of application, including 2 years of
experience as an independent investigator with independent peer-reviewed
support.  Support must be available to carry out the research project for
which the RCDA salary is provided.  This award may not substitute for other
sources of research support since the objective is to provide relief from
responsibilities that prevent full-time (not less than 80 percent basic,
clinical, or behavioral research) pursuit of an academic research career.  New
investigators and well-established investigators are not eligible for this
Award.
     
  o  Candidate is nominated by and an award is made to an institution on
     behalf of the candidate.
     
  o  Selection is by national competition.
     
  o  Salary is up to $50,000 per year plus fringe benefits.
     
  o  Award period is 5 years.
     
  o  Salary supplementation from non-federal funds is allowable.
     
  o  Indirect costs of 8 percent of total direct costs or actual rate,
     whichever is less, may be requested.
     
  o  RCDA applications may be submitted concurrently with a regular
     research grant application but must not be submitted concurrently
     with other career development awards, such as PSA, CIA, FIRST
     Award, or Academic Award.
     
  o  Use application form PHS 398 (Rev.  10/88) with RCDA instructions.
     
APPLICATION SUBMISSION AND REVIEW
     
The receipt dates are the traditional NIH dates:  February 1, June 1, and
October 1 for Council review October, February, and May, respectively.  The
PSA and CIA applications will be reviewed by the NHLBI Research Manpower
Review Committee or other appropriate Institute review committees.  RCDA
applications will be reviewed for scientific merit through the regular NIH
peer review system in the Division of Research Grants.
     
Applications submitted in response to this announcement should be identified
by typing P.A./Research Career Awards in Thrombosis PA-90-01 on line 2 of the
face page.
     
For the PSA and CIA the original and four copies of the application should be
mailed to:
     
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**
     
Two copies of the application should be mailed to:
     
Fann Harding, Ph.D.
National Heart, Lung, and Blood Institute
Division of Blood Diseases and Resources
Federal Building, Room 5A08
Bethesda, MD  20892
Telephone:  (301) 496-1817

     
             NIH GUIDE - Vol. 19, No. 14, April 6, 1990 - Page 12
For the RCDA, submit the original and six copies of the application to DRG at
the address above.
     
The programs of the Division of Blood Diseases and Resources of the National
Heart, Lung, and Blood Institute are identified in the Catalog of Federal
Domestic Assistance, number 13.839.  Awards will be made under the authority
of the Public Health Service Act, Section 301 (42 USC 241) and administered
under PHS grant policies and Federal regulations, most specifically 42 CFR
Part 52 and 45 CFR Part 74.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372, or to Health
Systems Agency Review.

INVESTIGATIONS INTO THE BIOLOGY OF THE RENAL MICROVASCULATURE
     
PA:  PA-90-02
     
P.T. 34; K.W. 0785095, 1002004, 1002008, 0785050, 1002019, 0765035, 0710030
     
National Institute of Diabetes and Digestive and Kidney Diseases
     
The Division of Kidney, Urologic and Hematologic Diseases (DKUHD) of the
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
announces the availability of an ongoing Program Announcement (PA) on the
above subject.
     
BACKGROUND
     
Intrarenal microcirculatory forces are responsible for formation of filtrate
at the glomerulus, reabsorption of fluid by the peritubular capillaries, and
maintenance of the hyperosmotic environment in the kidney medulla.
Accordingly, mechanisms that regulate these forces in the renal vascular beds
are of paramount importance to the kidney's homeostatic function.  Acting on
the hydrodynamic force derived from the heart, the smooth muscle cells of
these microcirculatory systems respond to neural, hormonal, and intrinsic
stimuli to maintain an appropriate blood flow through each "nephrovascular"
unit and an optimal hydrostatic pressure within the glomerular capillaries.
     
In recent years considerable attention has been focused on the renal
microvasculature in attempts to gain insight into the function of such
difficult to explore entities such as the macula densa and the juxtaglomerular
apparatus.  A growing body of evidence suggests that the renal
microvasculature is the site of the integrative regulatory mechanisms involved
in the kidney's homeostatic mechanisms.  In addition, disturbances in the
microvasculature at all levels in the kidney, and particularly in the
glomerulus, appear to underlie several important renal disorders.  Therefore,
it is the objective of this PA to encourage increased research activity
directed toward the elucidation of the renal microvasculature.
     
RESEARCH GOALS AND SCOPE
     
This special grant program will support both fundamental and clinical
research.  An emphasis of this initiative, however, is to foster extensive
collaboration between individuals in the basic sciences, including
biochemistry, cell biology, embryology, endocrinology, genetics, molecular
biology, pathology, pharmacology, renal physiology and pathophysiology.  It is
the intent of this solicitation to engage investigators with diverse research
interests but who wish to apply their technologies and expertise in
elucidating and extending the current understanding of the renal
microvasculature.  To that end the following are some of the objectives of
this solicitation that are being encouraged:
     
o Development of model culture systems that maintain the in vivo phenotype of
the cells involved in microcirculation and filtration, i.e., epithelial and
endothelial cells from various nephron segments, mesangial cells, etc.;
     
o Studies to identify molecular components participating in cell-cell and
cell-matrix interactions in normal and disease states;
     
o Studies aimed at defining in vivo roles for specific cytokines, growth
factors and eicosanoid or other mediators in physiologic microvascular
responses and in human renal diseases and animal models of renal disease,
especially through techniques identifying in situ production, local release
and/or verifiable action of specific mediators.  Also, develop in vivo methods
for the assessment of intracellular signalling events critical to vascular
control systems and elaboration of growth factors;

     
             NIH GUIDE - Vol. 19, No. 14, April 6, 1990 - Page 13
Beyond description of mediators, additional approaches may address
consequences for the local renal microvasculature arising from over-expression
of individual mediators as might occur with transgenic animal models,
retroviral expression, or other methods.
     
o Studies of the roles of coagulation, fibrinolytic, complement and other
mediator systems in specific models of glomerular injury;
     
The above are examples only and should not be viewed as all inclusive.
     
MECHANISMS OF SUPPORT
     
Support for this program will be through the grant-in-aid and will be governed
by the current policies of grant programs of the National Institutes of Health
(NIH).  New applications may be submitted for the traditional,
investigator-initiated research project grant (R01) and First Independent
Research Support and Transition (FIRST) Awards (R29).  Under these mechanisms,
the applicants will plan, direct, and conduct the research programs.  The
project period during which the research will be conducted should adequately
reflect the time required to accomplish the stated goals and be consistent
with the policy for grant support.  Support will be provided up to five years
(renewable for subsequent periods) subject to the availability of funds and
progress achieved.
     
Research grant applications may be submitted by both nonprofit and
profit-making organizations and institutions, State and local governments and
their agencies, and eligible agencies of the Federal government.
     
APPLICATION AND REVIEW PROCEDURES
     
The Division of Research Grants, NIH, serves as a central point for receipt of
applications for most discretionary PHS grant programs.  Applications in
response to this announcement will be assigned to an Initial Review Group
(IRG) in accordance with established PHS Referral Guidelines.  The IRGs,
consisting primarily of non-Federal scientific and technical experts, will
provide the peer review for scientific merit of the proposed research,
potential significance of the research findings, adequacy of methodology,
availability of necessary facilities, and the qualifications of the research
team.  A secondary review will be by an appropriate National Advisory Council
that will consider the Institute's mission, policy and program relevance to
its research needs.
     
Applications must be submitted using Form 398 (rev.  10/88), "Application for
Public Health Service Grant", available in the business or grants office of
most academic or research institutions, or from the Office of Grants
Inquiries, Division of Research Grants, National Institutes of Health, 5333
Westbard Avenue, Bethesda, MD 20892.  In order to assure proper identification
of the application, line 2 of the application form should state "Renal
Microvasculature Program Announcement, PA-90-02" and check the "YES" box.
     
The first receipt date for applications will be June 1, 1990, with Initial
Review Group review in September-October 1990 and Advisory Council review
January-February 1991.  The earliest requested begin-date should be April 1,
1991.  Thereafter, the regular NIH receipt dates for grant applications will
pertain:  October 1, February 1 and June 1 of each year.
     
The original and six copies of the application are to be sent to:
     
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**
     
Prior to submitting applications, applicants are encouraged to contact:
     
M. James Scherbenske, Ph.D.
Renal Physiology/Cell Biology Program Director
DKUHD/NIDDK
Westwood Building, Room 621
Bethesda, MD  20892
Telephone:  (301) 496-7458
     
**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF
RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS THE
CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH.  APPLICANTS WHO
USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S
REQUIREMENTS FOR SHOWING A STREET ADDRESS.  THE ADDRESS FOR THE WESTWOOD
BUILDING IS:  5333 Westbard Avenue
              Bethesda, Maryland 20816
             NIH GUIDE - Vol. 19, No. 14, April 6, 1990 - Page 14